Literature DB >> 17456810

JCAHO tweaks emergency departments' pneumonia treatment standards.

Mike Mitka.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456810     DOI: 10.1001/jama.297.16.1758

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  7 in total

1.  Root cause analysis and subsequent intervention to improve first dose antibiotic turnaround time for hospitalized pediatric patients.

Authors:  Abigail A Dee; Brian Kelly; Christian Hampp
Journal:  J Pediatr Pharmacol Ther       Date:  2010-07

2.  Linking joint commission inpatient core measures and national patient safety goals with evidence.

Authors:  Andrew L Masica; Kathleen M Richter; Paul Convery; Ziad Haydar
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-04

Review 3.  Hospital mortality: when failure is not a good measure of success.

Authors:  Kaveh G Shojania; Alan J Forster
Journal:  CMAJ       Date:  2008-07-15       Impact factor: 8.262

4.  [Pneumonia in the elderly: results of quality improvement program for a geriatric department in Lower Saxony 2006-2009].

Authors:  M Gogol; D Schmidt; A Dettmer-Flügge; B Vaske
Journal:  Z Gerontol Geriatr       Date:  2011-08       Impact factor: 1.281

5.  Reporting hospitals' antibiotic timing in pneumonia: adverse consequences for patients?

Authors:  Mark W Friedberg; Ateev Mehrotra; Jeffrey A Linder
Journal:  Am J Manag Care       Date:  2009-02       Impact factor: 2.229

Review 6.  Evaluation of the Quality of Care among Hospitalized Adult Patients with Community-Acquired Pneumonia in Korea.

Authors:  Ji Young Hong; Young Ae Kang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2018-06-19

7.  Time for first antibiotic dose is not predictive for the early clinical failure of moderate-severe community-acquired pneumonia.

Authors:  A H W Bruns; J J Oosterheert; W N M Hustinx; C A J M Gaillard; E Hak; A I M Hoepelman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-03-12       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.